H.C. Wainwright downgraded Unity Biotechnology (UBX) to Neutral from Buy with a price target of $2, down from $4. The firm cites the company’s management transitions and forthcoming platform direction for the downgrade. Following the previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients not achieving non-inferiority at the average of weeks 20 and 24 primary analysis, H.C. Wainwright downgraded Unity.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- Unity Biotechnology downgraded to Neutral from Outperform at Mizuho
- Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study
- Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE
- Unity Biotechnology Reports Q1 2025 Financials and Study Updates
- Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study